Hepion Pharmaceuticals Inc. (HEPA) - Forward P/S Multiple

Hepion Pharma - graphic logo of issuer HEPA

This P/S forecast chart demonstrates a sharp decline due to the failure of the lead drug trials and asset liquidation. Previously, the capital reliability of Hepion Pharmaceuticals (HEPA) was supported by a strict budget and patents. However, geopolitical fractures have hindered biomaterial logistics and global research. The current level of reflects the latest metric value, capturing a shift in market consensus.

HEPA Hepion Pharmaceuticals, Inc.: Future Price to Revenue in the range 07/04/2022 - 11/17/2026

HEPA (Hepion Pharmaceuticals Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company valuation:Hepion Pharmaceuticals, Inc. (HEPA)
Original product of Hepion Pharmaceuticals, Inc.

The forward P/S multiple compares current market capitalization with expected revenue, allowing investors to assess the premium paid for future cash flows. By analyzing the future P/S multiple, one can gauge market expectations for Hepion Pharmaceuticals (HEPA), where asset value depends directly on the efficiency of pharmaceutical logistics and the integrity of drugs during delivery.